Cardiol Therapeutics completes $15.1 million IPO

1 minute read
20 December 2018
Client work

Team:

Brett Kagetsu, Tara Amiri-Khaledi

On December 20, 2018, Cardiol Therapeutics Inc. (TSX: CRDL) announced that it had completed its initial public offering on the Toronto Stock Exchange, having issued units and warrants for aggregate gross proceeds of $15,142,327. The IPO was made through a syndicate of underwriters led by AltaCorp Capital Inc. and including Mackie Research Capital Corporation, Raymond James Ltd., Echelon Wealth Partners Inc. and Paradigm Capital Inc.

Cardiol is a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer.

Gowling WLG advised Cardiol with respect to this transaction with a team that included Brett Kagetsu and Tara Amiri.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Cannabis, Capital Markets

Team

Related Insights & Resources

View all insights Related Insights & Resources
Client work
14 March 2024 Innocan Pharma closes non-brokered private placement
paperclip chain Articles
31 January 2024 Supply chain transparency reporting begins in Canada
Client work
20 October 2023 Innocan Pharma closes brokered LIFE offering

Team

Download or print PDF